论文部分内容阅读
目的:研究分析低分子肝素用于原发性肾小球的治疗效果。方法:选择2013年4月-2014年4月期间在我院接受治疗的42例原发性肾小球肾炎患者,随机性将其分成对照组(应用洛汀新、强的松治疗)与观察组(应用低分子肝素治疗),每组各有患者21例。结果:经8周治疗后,两组患者的内生肌酐清除率(英简Ccr)、肾脏病理均有所改善,且观察组较对照组改善的更为明显(P<0.05);观察组患者的抗Xa因子活性(英简AXa)水平显著性高于对照组,差异P<0.05有统计学意义。结论:低分子肝素用于原发性肾小球肾炎疾病的治疗,能够缓解该病的病理损害,延缓肾功能的病变进展,在临床治疗中具有重大意义。
Objective: To study the therapeutic effect of low molecular weight heparin on primary glomeruli. Methods: Forty-two patients with primary glomerulonephritis treated in our hospital from April 2013 to April 2014 were randomly divided into control group (treated with Lotensin and prednisone) and observation Group (application of low molecular weight heparin treatment), each with 21 patients in each group. Results: After 8 weeks of treatment, the endogenous creatinine clearance (Ccr) and renal pathology were improved in both groups, and the observation group was more obvious than the control group (P <0.05). In the observation group Of anti-factor Xa activity (British Jane AXa) was significantly higher than the control group, the difference P <0.05 was statistically significant. Conclusion: The application of low molecular weight heparin in the treatment of primary glomerulonephritis disease can alleviate the pathological damage of the disease and delay the progression of renal function, which is of great significance in clinical treatment.